Jody A. Charnow, Editor

Real-world data validate recently reported findings from clinical trials.

Patients who underwent ureteroscopic management of low-risk UTUC had a 5-year cancer-specific survival rate of 92.6%.

Overall and disease-free survival among patients undergoing surgical resection for MIUC is low despite increasing use of neoadjuvant chemotherapy.

After a median time of 28.4 months, 40.6% of patients treated with pembrolizumab for high-risk nonmuscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin (BCG) therapy had a complete response to the drug, and the median duration of response was 16.2 months.

Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no protective effect.

FDA has approved rucaparib for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer in men previously treated with androgen-receptor directed therapy and taxane-based chemotherapy.

Obese men with metastatic castration-resistant prostate cancer have superior cancer-specific and overall survival than their overweight and normal-weight counterparts, a study found.

Findings from a new study can help individualize prognoses for men with biochemical recurrence of prostate cancer after radical prostatectomy.

Cytoreductive radical prostatectomy following neoadjuvant androgen-deprivation therapy (ADT) in men with hormone-naïve low-volume metastatic prostate cancer improves survival long-term vs ADT alone, a study found.

Among patients who undergo treatment for T1a renal cell carcinoma, 5- and 10-year cancer-specific mortality rates rise with age across treatment modalities, a study found.